Type: Oral
Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: B Cell-directed CAR T Cell Therapies for ALL and for Autoimmunity
Hematology Disease Topics & Pathways:
Research, Clinical trials, Clinical Research
Methods: In this prospective single-arm clinical trial, patients with riPTR received a combination of murine anti-BCMA CAR T-cells and murine anti-CD19 CAR T-cells at a dose of 2×107 cells/kg. The efficacy and safety of this treatment were assessed. This study was registered at clinicaltrials.gov (identifier: NCT04846439).
Results: Twelve patients with riPTR received CAR T-cell treatment with a median follow-up of 33.5 (range, 13.5-34.5) months. Among these 12 patients, the median of the maximum mean fluorescence intensity (MFI) values of anti-human leukocyte antigen (HLA) antibodies decreased by 91.1%, from 15319 (range, 10807-20374) before CAR T-cell infusion to 1369 (range, 997-2923) at 4 months post-infusion (P=0.0001). And four months after CAR T-cell infusion, the median number of anti-HLA class I antibodies with an MFI > 5000 decreased significantly from 18 (range, 3-41) before infusion to 0 (range, 0-0) post-infusion (P=0.0005). Anti-HLA antibodies in all patients turned negative within 5 months after CAR T-cell therapy and have maintained negative for up to 30.5 months to date. After CAR T-cell treatment, the medians of the amount of platelet transfusions within 7 days and the duration of platelet count below 10×109/L were significantly lower (P = 0.0002, P = 0.001). Meanwhile, there was a significant increase in 14-hour corrected count increment (CCI) and no occurrence of 14-hour CCI below 5×109/L in all patients after the administration of CAR T-cells. RiPTR was completely corrected in all patients and never occurred during subsequent chemotherapy or transplantation. All patients who underwent transplantation achieved successful neutrophil and platelet engraftment. No patient developed grade ≥ 3 cytokine release syndrome. All patients experienced transient grade ≥ 3 cytopenia. Only 2 patients (16.7%) experienced infection. All adverse events were reversible and manageable.
Conclusions: CAR T-cell therapy could be well-tolerated and highly effective in overcoming riPTR and eradicating allo-antibodies, making it applicable to antibody-mediated diseases.
Disclosures: No relevant conflicts of interest to declare.